GlassScriptPhysician profile
Dinu C Nodit
NPI 1801848205
$1,794.66
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $939 · 2020: $398 · 2021: $412 · 2022: $45.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $362.11 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $307.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $184.67 | 2020-2021 | |
| Biogen, INC. | $132.02 | 2019 | |
| Neurelis, INC. | $81.88 | 2021 | |
| Alexion Pharmaceuticals, INC. | $75.73 | 2019 | |
| Abbvie INC. | $70.62 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $67.50 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $56.80 | 2019-2022 | |
| Amgen INC. | $51.74 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.92 | 2019-2021 | |
| Ucb, INC. | $44.90 | 2021 | |
| Avanir Pharmaceuticals, INC. | $44.75 | 2019 | |
| Genzyme Corporation | $43.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $38.06 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $31.10 | 2019 | |
| Celgene Corporation | $30.06 | 2021 | |
| Allergan, INC. | $25.05 | 2020 | |
| Banner Life Sciences, LLC | $21.54 | 2021 | |
| Emd Serono, INC. | $19.31 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.07 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.99 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.73 | 2019 | |
| Assertio Therapeutics, INC. | $13.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dinu Nodit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.